CLAIMS

What is claimed is:

1. A therapeutic compound comprising:

a drug moiety comprising paclitaxel,

at least one polypeptide drug carrier moiety having 70% by total weight of the polypeptide drug carrier, glutamic acid, and 30% by total weight by total weight of the polypeptide drug carrier, aspartic acid, wherein at least one glutamic acid is directly bonded to aspartic acid, and

the drug moiety being covalently linked to the carrier moiety.

2. The therapeutic compound of claim 1, wherein the drug carrier moiety comprises a molecular weight in the range of about 20,000 daltons to about 50,000 daltons.

3. The therapeutic compound of claim 1, wherein the drug moiety comprises from about 10 percent to about 60 percent, by weight, of the therapeutic compound.

4. The therapeutic compound of claim 1, wherein the drug moiety comprises from about 20 percent to about 50 percent, by weight, of the therapeutic compound.

5. The therapeutic compound of claim 1, wherein the drug moiety comprises from about 20 percent to about 40 percent, of the therapeutic compound.

6. The therapeutic compound of claim 1, wherein the amino acids can be in L form, or D form, or a racemic mixture of L and D forms.

7. The therapeutic compound of claim 1, wherein

the drug moiety comprises paclitaxel and is about 24 percent to about 30 percent, by weight, of the therapeutic compound, and

the molecular weight of the therapeutic compound is from about 26,000 to about 30,000 daltons.

8. A method for improving the solubility of a drug moiety comprising the steps of:

covalently conjugating the drug moiety with at least one polypeptide drug carrier moiety, thereby creating a therapeutic compound, the therapeutic compound comprising:

the drug moiety comprising paclitaxel, and

at least one polypeptide drug carrier moiety having 70% by total weight of the polypeptide drug carrier, glutamic acid, and 30% by total weight by total weight of the polypeptide drug carrier, aspartic acid, wherein at least one glutamic acid is directly bonded to at least one aspartic acid, and

the drug moiety being covalently linked to the carrier moiety.

9. The method of claim 8, wherein the drug carrier moiety comprises a molecular weight in the range of about 20,000 daltons to about 50,000 daltons.

10. The method of claim 8, wherein the water solubility of the therapeutic compound is greater than the water solubility of the drug moiety.

11. The method of claim 8, wherein

the drug moiety comprises paclitaxel and is about 24 percent to about 30 percent, by weight, of the therapeutic compound, and

the molecular weight of the therapeutic compound is from about 26,000 to about 30,000 daltons.

12. A method for treating a condition comprising the steps of:

administering a therapeutically effective amount of a therapeutic compound comprising:

a drug moiety comprising paclitaxel, and

at least one polypeptide drug carrier moiety having 70% by total weight of the polypeptide drug carrier, glutamic acid, and 30% by total weight by total weight of the polypeptide drug carrier, aspartic acid, and wherein at least one glutamic acid is directly bonded to at least one aspartic acid, and

the drug moiety being covalently linked to the carrier moiety.

13. The method of claim 12, wherein the drug carrier moiety comprises a molecular weight in the range of about 20,000 daltons to about 50,000 daltons.

14. The method of claim 12, wherein the condition is a prostate tumor.

15. The method of claim 12, wherein

the drug moiety comprises paclitaxel and is about 24 percent to about 30 percent, by weight, of the therapeutic compound, and

the molecular weight of the therapeutic compound is from about 26,000 to about 30,000 daltons.